1-phenyl-5-trifluoromethyl-3-pyrazolecarboxylic acid | 497833-13-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-phenyl-5-trifluoromethyl-3-pyrazolecarboxylic acid
• 英文别名: 1-phenyl-5-(trifluoromethyl)-1H-pyrazole-3-carboxylic acid；1-phenyl-5-(trifluoromethyl)pyrazole-3-carboxylic acid
• CAS: 497833-13-3
• 化学式: C₁₁H₇F₃N₂O₂
• 分子量: 256.184
• InChiKey: IGZSBMSFNFCZRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-bromo-1-phenyl-5-trifluoromethyl-3-pyrazolecarboxylic acid 在 sodium hydroxide 、 锌 作用下， 以 水 为溶剂， 反应 6.0h， 以32%的产率得到1-phenyl-5-trifluoromethyl-3-pyrazolecarboxylic acid
  参考文献：
  名称：

  可切换的反应性：三氟甲基取代吡唑的位点选择性功能化

  摘要：

  现代有机金属方法能够将简单的杂环起始材料区域灵活地转化为异构体和同系物家族。取决于试剂的选择，1-甲基-5-(三氟甲基)吡唑主要或仅在杂环的4-位或在氮连接的Me基团上经历去质子化和随后的羧化。类似地，1-苯基-5-(三氟甲基)吡唑和3-甲基-1-苯基-5-(三氟甲基)吡唑在杂环4-位被二异丙基氨基锂选择性攻击，在4-位被丁基锂和Ph 环的正交位置。相比之下，1-甲基-3-（三氟甲基）吡唑的金属化仅发生在 5 位，无论是有机金属碱还是金属氨化物碱。如果将溴引入杂环或芳基中，则其他位点可进行功能化。戒指。4-溴-1-甲基-5-（三氟甲基）吡唑、4-溴-1-甲基-3-（三氟甲基）吡唑、4-溴-1-甲基-5-（三氟甲基）吡唑和1-(2-溴苯基)-5-(三氟甲基)吡唑。[在 SciFinder (R) 上]

  DOI：

  10.1002/1099-0690(200209)2002:17<2913::aid-ejoc2913>3.0.co;2-d

文献信息

• Monoacylglycerol Lipase Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20200102311A1

  公开（公告）日：2020-04-02

  Bridged compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein R 2 , R 3 R 4 , R 5 and R 6 are defined herein.

  桥接化合物，其结构式为(I)和(II)，包含它们的药物组合物，制造它们的方法，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、障碍和状况的方法，如与疼痛、精神障碍、神经障碍（包括但不限于重性抑郁障碍、难治性抑郁、焦虑性抑郁、双相情感障碍）、癌症和眼科疾病相关的方法。 其中R2、R3、R4、R5和R6的定义如下。
• [EN] NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1).<br/>[FR] NOUVEAUX AMIDES HETEROCYCLIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2004096784A1

  公开（公告）日：2004-11-11

  The present invention relates to new compounds of formula I, wherein R1 to R8 are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

  本发明涉及公式I的新化合物，其中R1至R8如公式I中所定义，或其盐、溶剂合物或溶剂化合盐，以及用于其制备的新中间体，含有所述化合物的药物组合物以及所述化合物在治疗中的用途。
• Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1)
  申请人：Besidski Yevgeni

  公开号：US20060223868A1

  公开（公告）日：2006-10-05

  Compounds of formula I, wherein R 1 , n, R 3 , R 4 , R 7 , R 8 and P are as defined in the specification, salts, solvates or solvated salts thereof, processes for their preparation, new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and the use of said compounds in therapy.

  本发明涉及公式I的化合物，其中R1，n，R3，R4，R7，R8和P如规范中所定义，以及其盐，溶剂合物或溶剂化盐，制备它们的方法，用于制备中使用的新中间体，含有上述化合物的制药组合物以及上述化合物在治疗中的使用。
• Primary Amines And Derivatives Thereof As Modulators Of The 5-HT2A Serotonin Receptor Useful For The Treatment Of Disorders Related Thereto
  申请人：TEEGARDEN BRADLEY

  公开号：US20120270861A1

  公开（公告）日：2012-10-25

  The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

  本发明涉及式(Ia)的某些化合物及其制药组合物，这些化合物调节5-HT2A 5-羟色胺受体的活性。这些化合物及其制药组合物用于治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性脑缺血发作、心绞痛、中风、心房颤动、血栓形成、哮喘或其症状、激动或其症状、行为障碍、药物诱导的精神病、兴奋性精神病、Gilles de la Tourette综合征、躁狂障碍、器质性或非器质性精神病、精神病、急性精神分裂症、慢性精神分裂症、非特异性精神分裂症及相关疾病以及睡眠障碍、糖尿病相关疾病、进行性多灶性白质脑病等方面的治疗方法。本发明还涉及与其他药物分别或同时给予的联合治疗5-HT2A 5-羟色胺受体相关疾病的方法。
• PRIMARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
  申请人：Teegarden Bradley

  公开号：US20140235622A1

  公开（公告）日：2014-08-21

  The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT 2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggreagation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, blood clot formation, asthma or symptoms thereof, agitation or a symptom thereof, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT 2A serotonin receptor associated disorders in combination with other pharmaceutical agents administered separately or together.

  本发明涉及公式（Ia）的某些化合物及其药物组合物，可调节5-HT2A 5-羟色胺受体的活性。这些化合物和药物组合物用于治疗血小板聚集、冠状动脉疾病、心肌梗死、短暂性缺血性发作、心绞痛、中风、房颤、血栓形成、哮喘或其症状、激动或其症状、行为障碍、药物诱导的精神病、兴奋性精神病、Gilles de la Tourette综合症、躁狂障碍、器质性或NOS精神病、精神病、急性精神分裂症、慢性精神分裂症、NOS精神分裂症及相关疾病、睡眠障碍、糖尿病相关疾病、进行性多灶性白质脑病等治疗方法。本发明还涉及与其他药物代理分别或联合给药治疗5-HT2A 5-羟色胺受体相关疾病的方法。